Volker Schirrmacher
#113,060
Most Influential Person Now
Researcher
Volker Schirrmacher's AcademicInfluence.com Rankings
Volker Schirrmacherphilosophy Degrees
Philosophy
#4813
World Rank
#7465
Historical Rank
Logic
#2192
World Rank
#3128
Historical Rank

Download Badge
Philosophy
Why Is Volker Schirrmacher Influential?
(Suggest an Edit or Addition)Volker Schirrmacher's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review) (2018) (481)
- THE REQUIREMENT OF MORE THAN ONE ANTIGENIC DETERMINANT FOR IMMUNOGENICITY (1969) (396)
- Bone marrow as a priming site for T-cell responses to blood-borne antigen (2003) (340)
- Cancer metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies. (1985) (300)
- Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow (2001) (290)
- Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. (1983) (265)
- Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IV and fibronectin (1982) (222)
- Human (HLA-A and HLA-B) and murine (H-2K and H-2D) histocompatibility antigens are cell surface receptors for Semliki Forest virus. (1978) (203)
- Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. (2004) (202)
- EGF receptor in neoplasia and metastasis (1993) (191)
- Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis (2002) (174)
- Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-Neuraminidase (2009) (169)
- Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo (1979) (166)
- Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus (1999) (160)
- Metastatic potential severely altered by changes in tumor cell adhesiveness and cell-surface sialylation (1983) (156)
- Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients (2001) (155)
- High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. (2005) (154)
- Different patterns of lectin binding and cell surface sialylation detected on related high- and low-metastatic tumor lines. (1983) (154)
- Nitric-oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome C release. (1999) (150)
- Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. (1995) (147)
- Tumor selective replication of Newcastle disease virus: Association with defects of tumor cells in antiviral defence (2006) (141)
- Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. (2007) (140)
- Further evidence for derepression of H–2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines (1976) (136)
- Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial (2008) (136)
- Tumor Infiltrating T Lymphocytes in Colorectal Cancer: Tumor-Selective Activation and Cytotoxic Activity In Situ (2006) (132)
- Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. (2005) (131)
- Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory (2005) (127)
- Heat-stable antigen (CD24) as ligand for mouse P-selectin. (1994) (126)
- H–2-like specificities of foreign haplotypes appearing on a mouse sarcoma after vaccinia virus infection (1976) (122)
- Effective subunit vaccines against an enveloped animal virus (1978) (121)
- Induction of Interferon-α and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Human Blood Mononuclear Cells by Hemagglutinin-Neuraminidase but Not F Protein of Newcastle Disease Virus (2002) (116)
- Co‐stimulatory effect of nitric oxide on endothelial NF‐κB implies a physiological self‐amplifying mechanism (1998) (116)
- Newcastle Disease Virus: A Promising Vector for Viral Therapy, Immune Therapy, and Gene Therapy of Cancer (2008) (114)
- Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. (2002) (111)
- Immunization with virus-modified tumor cells. (1998) (111)
- Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice.: Iv. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes (1979) (110)
- Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects (1986) (109)
- EblacZ tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells. (1998) (109)
- Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. (1994) (107)
- TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus 1 (2003) (106)
- Shifts in tumor cell phenotypes induced by signals from the microenvironment. Relevance for the immunobiology of cancer metastasis. (1980) (105)
- Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. (2004) (102)
- Antitumor Vaccination in Patients with Head and Neck Squamous Cell Carcinomas with Autologous Virus-Modified Tumor Cells (2004) (101)
- Proposed molecular basis of murine tumor cell-hepatocyte interaction. (1983) (101)
- Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy (2007) (100)
- Anti-CD2 antibodies induce T cell unresponsiveness in vivo (1991) (92)
- IMMUNE RESPONSES AGAINST NATIVE AND CHEMICALLY MODIFIED ALBUMINS IN MICE (1972) (92)
- Suggestive evidence that the highly metastatic variant ESB of the T‐cell lymphoma eb is derived from spontaneous fusion with a host macrophage (1984) (92)
- Caspase activation is required for nitric oxide-mediated, CD95(APO-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells. (1998) (90)
- Hepatocyte-tumor cell interaction in vitro. I. Conditions for rosette formation and inhibition by anti-H-2 antibody (1980) (88)
- Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. (2001) (88)
- Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. (2009) (87)
- Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. (1991) (86)
- Induction of HLA class‐II antigen expression on human carcinoma cell lines by IFN‐gamma (1985) (84)
- Nitric oxide-induced apoptosis in tumor cells. (2001) (79)
- T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. (2003) (78)
- p53 increases experimental metastatic capacity of murine carcinoma cells (1988) (74)
- Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta. (1990) (74)
- Maintenance of long‐term tumour‐specific T‐cell memory by residual dormant tumour cells (2005) (72)
- Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells (1985) (72)
- Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. (1997) (72)
- Newcastle disease virus activates macrophages for anti-tumor activity. (2000) (71)
- Expression and function of the neural cell adhesion molecule L1 in mouse leukocytes (1992) (70)
- Scattered micrometastases visualized at the single‐cell level: Detection and re‐isolation of lacZ‐labeled metastasized lymphoma cells (1994) (69)
- Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. (2002) (69)
- Superiority of the ear pinna over muscle tissue as site for DNA vaccination (1998) (69)
- Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage (1984) (68)
- Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! (2016) (68)
- Specific lymphocyte-activating determinants expressed on mouse macrophages (1975) (68)
- Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. (2003) (68)
- T-cell immunity in the induction and maintenance of a tumour dormant state. (2001) (66)
- Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells (2000) (66)
- Identification of asparagine-linked oligosaccharides involved in tumor cell adhesion to laminin and type IV collagen (1984) (66)
- Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes (1981) (66)
- The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. (2006) (64)
- Viral hemagglutinin augments peptide‐specific cytotoxic T cell responses (1993) (64)
- Quantitative in vitro assay for tumor cell invasion through extracellular matrix or into protein gels. (1988) (64)
- Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. (2009) (64)
- ICE-proteases mediate HTLV-I Tax-induced apoptotic T-cell death (1997) (63)
- Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. (2008) (63)
- High‐frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb) (1982) (62)
- Human T cell leukemia virus-I (HTLV-I) Tax-mediated apoptosis in activated T cells requires an enhanced intracellular prooxidant state. (1998) (61)
- Involvement of both heparanase and plasminogen activator in lymphoma cell‐mediated degradation of heparan sulfate in the subendothelial extracellular matrix (1986) (61)
- Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns of protective anti‐tumor immunity in vivo and of cytolytic T cells in vitro (1979) (61)
- In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients. (1991) (60)
- Qualitative differences in position of sialylation and surface expression of glycolipids between murine lymphomas with low metastatic (Eb) and high metastatic (ESb) potentials and isolation of a novel disialoganglioside (GD1 alpha) from Eb cells. (1986) (59)
- Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B. (1996) (59)
- Dynamic Differentiation of Activated Human Peripheral Blood CD8+ and CD4+ Effector Memory T Cells (2005) (59)
- Modification of tumor cells by a low dose of Newcastle Disease Virus. (1988) (59)
- CD4+ helper T cells are required for resistance to a highly metastatic murine tumor (1987) (58)
- Tumour cell–dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen‐glycol versus electro‐fusion protocols (2002) (58)
- Purification and identification of chemokines potentially involved in kidney‐specific metastasis by a murine lymphoma variant: induction of migration and NFκB activation (1998) (57)
- Tumor-Cell Number and Viability as Quality and Efficacy Parameters of Autologous Virus-Modified Cancer Vaccines in Patients With Breast or Ovarian Cancer (1997) (56)
- Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance (2015) (56)
- Ligand mediated activation of ectopic EGF receptor promotes matrix protein adhesion and lung colonization of rat mammary adenocarcinoma cells. (1995) (56)
- Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice (2007) (55)
- Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy (2019) (55)
- Monoclonal antibodies which prevent experimental lung metastases (1984) (54)
- Postoperative active specific immunization in colorectal cancer patients with virus‐modified autologous tumor‐cell vaccine. First clinical results with tumor‐cell vaccines modified with live but avirulent newcastle disease virus (1990) (54)
- Interactions of Fc receptors with antibodies against Ia antigens and other cell surface components (1975) (53)
- Sialoadhesin-positive host macrophages play an essential role in graft-versus-leukemia reactivity in mice. (1999) (53)
- Different expression of Lyt differentiation antigens and cell surface glycoproteins by a murine T lymphoma line and its highly metastatic variant (1982) (52)
- Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA. (2003) (51)
- Lymphoma cell interaction with cultured vascular endothelial cells and with the subendothelial basal lamina: attachment, invasion and morphological appearance. (1983) (51)
- Cellular distribution and biological activity of epidermal growth factor receptors in A431 cells are influenced by cell‐cell contact (1990) (51)
- Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice X. Immunoselection of tumor variants differing in tumor antigen expression and metastatic capacity (1980) (50)
- Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. (1992) (50)
- Liver endothelial cells participate in T‐cell‐dependent host resistance to lymphoma metastasis by production of nitric oxide in vivo (1995) (50)
- Bone marrow microenvironment facilitating dendritic cell: CD4 T cell interactions and maintenance of CD4 memory. (2004) (50)
- Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice (2003) (50)
- Characterization and isolation of a trypsin-like serine protease from a long-term culture cytolytic T cell line and its expression by functionally distinct T cells. (1986) (49)
- Somatic cell fusion as a source of genetic rearrangement leading to metastatic variants (2004) (49)
- Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells. (2002) (49)
- DETERMINATION OF ANTIBODY CLASS IN A SYSTEM OF COOPERATING ANTIGENIC DETERMINANTS (1970) (47)
- The bacterial lacZ gene: An important tool for metastasis research and evaluation if new cancer therapies (1998) (47)
- Antibody 12‐15 cross‐reacts with mouse Feγ receptors and CD2: study of thymus expression, genetic polymorphism and biosynthesis of the CD2 protein (1989) (46)
- Characterization of cellular and extracellular plasma membrane vesicles from a non-metastasizing lymphoma (Eb) and its metastasizing variant (ESb). (1985) (46)
- Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study (2009) (46)
- Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. (2006) (45)
- Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host (2013) (45)
- Cognate interactions between memory T cells and tumor antigen‐presenting dendritic cells from bone marrow of breast cancer patients: Bidirectional cell stimulation, survival and antitumor activity in vivo (2003) (45)
- Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors (2004) (45)
- Interferon production in the murine mixed lymphocyte culture. I. Interferon production caused by differences in the H‐2 K and H‐2 D region but not by differences in the I region or the M locus (1979) (44)
- Prospects for cytokine and chemokine biotherapy. (1997) (44)
- Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. (2002) (43)
- Analysis of cell‐surface sugar receptor expression by neoglycoenzyme binding and adhesion to plastic‐immobilized neoglycoproteins for related weakly and strongly metastatic cell lines of murine tumor model systems (1990) (42)
- Tumor response and 4 year survival-data of patients with advanced renal-cell carcinoma treated with autologous tumor vaccine and subcutaneous R-IL-2 and IFN-alpha(2b). (1995) (42)
- Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. (2007) (42)
- A mouse hepatocyte carbohydrate‐specific receptor and its interaction with liver‐metastasizing tumor cells (1983) (42)
- Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine (2000) (42)
- Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer (2013) (41)
- A rapid method for the isolation of metastasizing tumour cells from internal organs with the help of isopycnic density-gradient centrifugation in Percoll. (1981) (41)
- Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. (1995) (40)
- Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VII. Interaction of metastasizing and nonmetastasizing tumors with normal tissue in vitro. (1980) (39)
- Active specific immunotherapy with Newcastle-diseasevirus-modified autologous tumor cells following resection of liver metastases in colorectal cancer (1992) (39)
- Glycoconjugates of murine tumor lines with different metastatic capacities. I. Differences in fucose utilization and in glycoprotein patterns (1984) (38)
- Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. (2011) (38)
- Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. (2006) (37)
- Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. (2011) (37)
- DNA vaccination with asparaginyl endopeptidase (Sm32) from the parasite Schistosoma mansoni: anti-fecundity effect induced in mice. (2001) (37)
- Changes in tumor cell adhesiveness affecting speed of dissemination and mode of metastatic growth. (1988) (37)
- Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus. (1998) (36)
- Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. (1997) (36)
- Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity (1987) (35)
- Effective immune rejection of advanced metastasized cancer. (1995) (35)
- Differential expression of endogenous sugar‐binding proteins (lectins) in murine tumor model systems with metastatic capacity (1987) (35)
- STUDIES ON H‐2 SPECIFICITIES ON MOUSE TUMOUR CELLS BY A NEW MICRORADIOASSAY * (1977) (34)
- Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation. (1998) (34)
- Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. (2008) (34)
- Plasmin in pericellular proteolysis and cellular invasion. (1994) (33)
- Stimulation of human natural interferon-α response via paramyxovirus hemagglutinin lectin-cell interaction (2002) (33)
- Evidence for a plasma membrane redox system on intact ascites tumor cells with different metastatic capacity. (1981) (33)
- Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function (2014) (33)
- A NEW SENSITIVE ASSAY FOR ANTIBODY AGAINST CELL SURFACE ANTIGENS BASED ON INHIBITION OF CELL-DEPENDENT ANTIBODY-MEDIATED CYTOTOXICITY (1974) (33)
- Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns. (1990) (32)
- A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes (2006) (32)
- Detection and Functional Analysis of Tumor Infiltrating T-Lymphocytes (TIL) in Liver Metastases from Colorectal Cancer (2008) (32)
- Antigenic variation in cancer metastasis: immune escape versus immune control (2004) (32)
- Cytogenetic changes during tumor progression towards invasion, metastasis and immune escape in the Eb/ESb model system (1982) (32)
- Differences in the expression of histocompatibility antigens on mouse lymphocytes and tumor cells: immunochemical studies (1979) (32)
- In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein. (2006) (31)
- Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VIII. Expression and shedding of Fc gamma receptors on metastatic tumor cell variants. (1979) (31)
- Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus (2005) (31)
- Motility and invasive potency of murine T‐lymphoma cells: effect of microtubule inhibitors. (1994) (31)
- Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients (2017) (31)
- Inhibition of liver tumor cell colonization in two animal tumor models by lectin blocking with D-galactose or arabinogalactan (1988) (31)
- Recruitment and activation of tumor-specific immune T cells in situ. CD8+ cells predominate the secondary response in sponge matrices and exert both delayed-type hypersensitivity-like and cytotoxic T lymphocyte activity. (1989) (30)
- Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report (2014) (30)
- Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism (2020) (30)
- Immediate effects of reversible HTLV-ITax function: T-cell activation and apoptosis (1995) (29)
- Modification of tumor cells by a low dose of Newcastle disease virus (2004) (29)
- T Cell Memory, Anergy and Immunotherapy in Breast Cancer (2002) (29)
- Differences between graft-versus-leukemia and graft-versus-host reactivity. I. Interaction of donor immune T cells with tumor and/or host cells. (1997) (29)
- Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-gamma. (2006) (29)
- Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo (2007) (29)
- CYTOTOXIC IMMUNE CELLS WITH SPECIFICITY FOR DEFINED SOLUBLE ANTIGENS (1974) (29)
- Cytotoxic immune cells with specificity for defined soluble antigens. II. Chasing the killing cells. (1973) (28)
- Randomized clinical studies of anti-tumor vaccination: state of the art in 2008 (2009) (28)
- Skin-specific promoters for genetic immunisation by DNA electroporation. (2009) (28)
- Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report. (2015) (28)
- Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis. (1996) (28)
- Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN‐α/β (1994) (27)
- Tumour‐Specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens (1993) (27)
- Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis (2020) (27)
- Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man versus immune evasion by Ebola virus (Review). (2015) (27)
- Less Can Be More: The Hormesis Theory of Stress Adaptation in the Global Biosphere and Its Implications (2021) (27)
- Effect of thymus factor on human precursor T lymphocytes (1975) (27)
- Induction of CD44 expression by the epstein‐barr virus latent membrane protein LMP1 is associated with lymphoma dissemination (1995) (27)
- Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity. (2011) (26)
- Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. V. Transfer of protective immunity with H‐2 identical immune T cells from B10.D2 mice (1979) (26)
- T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. (2005) (26)
- Active Specific Immunotherapy with Autologous Tumor Cell Vaccines Modified by Newcastle Disease Virus: Experimental and Clinical Studies (1989) (26)
- Pattern and load of spontaneous liver metastasis dependent on host immune status studied with a lacZ transduced lymphoma. (1994) (26)
- Activated endothelial cells induce apoptosis in lymphoma cells. (1997) (26)
- Immunity and metastasis: in situ activation of protective T cells by virus modified cancer vaccines. (1992) (25)
- Expression of epidermal growth-factor receptor correlates with metastatic potential of 13762nf rat mammary adenocarcinoma cells. (1994) (25)
- Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein. (2005) (25)
- Possible cell surface receptor for Friend murine leukemia virus isolated with viral envelope glycoprotein complexes (1980) (25)
- Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages. (1998) (25)
- Structural basis for altered soybean agglutinin lectin binding between a murine metastatic lymphoma and an adhesive low malignant variant. (1987) (25)
- Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. (2012) (24)
- Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine. (1998) (24)
- Dynamic expression changes in vivo of adhesion and costimulatory molecules determine load and pattern of lymphoma liver metastasis. (1996) (24)
- Characterization of an extracellular matrix-degrading protease derived from a highly metastatic tumor cell line. (1985) (23)
- Redox events in HTLV-1 Tax-induced apoptotic T-cell death. (2002) (23)
- An analysis of autologous T‐cell anti‐tumour responses in colon‐carcinoma patients following active specific immunization (ASI) (1992) (23)
- Targeting anti-tumor DNA vaccines to dendritic cells via a short CD11c promoter sequence. (2009) (23)
- Expression of L1 cell adhesion molecule is associated with lymphoma growth and metastasis (1993) (23)
- Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response. (1988) (23)
- Tumor cell vaccination for gynecological tumors. (1993) (22)
- Nucleocytoplasmic transport of HTLV-1 RNA is regulated by two independent LTR encoded nuclear retention elements (1998) (22)
- Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine. (2005) (22)
- Tumor‐specific T‐cell clones recognize different protein determinants of autologous human malignant melanoma cells (1990) (22)
- The extended packaging sequence of MoMLV contains a constitutive mRNA nuclear export function (1998) (22)
- Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged (2020) (21)
- Characteristics of alloantigens and cellular mechanisms responsible for gamma-interferon production in primary murine MLC. (1981) (21)
- High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules. (2004) (21)
- Rapid effects of EGF on cytoskeletal structures and adhesive properties of highly metastatic rat mammary adenocarcinoma cells (2004) (21)
- A new sensitive assay for antibody against cell surface antigens based on inhibition of cell-dependent antibody-mediated cutotoxicity. II. Mechanism. (1975) (21)
- Ligand-induced activation of epidermal growth factor receptor in intact rat mammary adenocarcinoma cells without detectable receptor phosphorylation. (1992) (21)
- Association of CD2 and T200 (CD45) in mouse T lymphocytes. (1990) (21)
- Pattern and load of spontaneous liver metastasis dependent on host immune status studied with a lacZ transduced lymphoma (1994) (20)
- Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus. (2009) (20)
- New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells. (1987) (20)
- Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus. (2009) (20)
- New insights into tumor-host interactions in lymphoma metastasis (1996) (20)
- Inheritance of immunogenicity and metastatic potential in murine cell hybrids from the T-lymphoma ESb08 and normal spleen lymphocytes. (1984) (20)
- An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. (2008) (19)
- Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein. (2005) (19)
- A role for sialoadhesin-positive tissue macrophages in host resistance to lymphoma metastasis in vivo. (1996) (19)
- Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine (2005) (19)
- In-situ activated macrophages are involved in host-resistance to lymphoma metastasis by production of nitric-oxide. (1995) (18)
- In Vivo 1H‐NMR microimaging with respiratory triggering for monitoring adoptive immunotherapy of metastatic mouse lymphoma (1997) (18)
- Activation of platelet heparitinase by tumor cell-derived factors. (1991) (18)
- Expression of Ia antigens in a murine T-lymphoma variant. (1985) (18)
- Studies on interleukin 2 receptor expression and IL-2 production by murine T cell lymphomas. (1985) (18)
- Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures. (1999) (18)
- Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. II. Influence of minor histocompatibility antigens on tumor resistance, gamma-interferon induction and cytotoxic response. (1981) (18)
- Functional and in situ evidence for nitric oxide production driven by CD40-CD40L interactions in graft-versus-leukemia reactivity. (2000) (18)
- Loss of endogenous mouse mammary tumor virus superantigen increases tumor resistance. (1998) (17)
- Cancer Immunotherapy: Battling Tumors with Gene Vaccines (2005) (17)
- The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination. (2010) (17)
- Inhibition of nitric-oxide-mediated apoptosis in Jurkat leukemia cells despite cytochrome c release. (2001) (17)
- Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals. (1989) (17)
- Antibody targeting to the murine lymphoma ESb‐MP: Increased accumulation due to reduced internauzation into lymphoma cells as compared to normal lymphoid cells (1988) (16)
- Syngeneic tumor cells can induce alloreactive T killer cells: a biological role for transplantation antigens. (1980) (16)
- Tumor immunology: Paul Ehrlich's heritage. (1989) (16)
- Integration of a virus membrane protein intothe lipid bilayer of target cells as a prerequisite for immune cytolysis. Specific cytolysis after virosome- target cell fusion (1979) (16)
- Further evidence for depression of H-2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines. (1976) (16)
- Gene transfer and genetic modification of embryonic stem cells by Cre‐ and Cre‐PR‐expressing MESV‐based retroviral vectors (2004) (16)
- Strong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: results from a phase Ⅰ clinical study. (2015) (16)
- Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus. (2011) (16)
- Growth and metastasis of human tumors in nude mice following tumor‐cell inoculation into a vascularized polyurethane sponge matrix (1988) (15)
- ACTIVATED T LYMPHOCYTES EXPRESS NEW SURFACE DETERMINANTS WHICH REACT WITH HETEROLOGOUS ANTI‐B CELL SERUM (1975) (15)
- Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity. (2011) (15)
- The activation domain of a hormone inducible HTLV-1 Rex protein determines colocalization with the nuclear pore. (1997) (15)
- Tumour targeting with antibody-coupled liposomes: Failure to achieve accumulation in xenografts and spontaneous liver metastases (1990) (15)
- The immune response against hapten-autologous protein conjugates in the mouse. IV. Thymus dependency of the primary response to hapten-autologous albumin conjugates. (1973) (15)
- Recruitment and activation of tumor‐specific immune t cells in situ: Functional studies using a sponge matrix model (1989) (14)
- Gamma-irradiation suppresses T-cell mediated protective immunity against a metastatic tumor in the afferent phase of the immune-response but enhances it in the efferent phase when given before immune cell transfer. (1994) (14)
- Cytotoxic immune cells with specificity for defined soluble antigens. V. Interaction of antibody with the cytotoxic effector cells in immune or non-immune mouse spleen cells. (1974) (14)
- Tumor vaccine design: concepts, mechanisms, and efficacy testing. (1995) (14)
- Characterization of cellular and extracellular plasma membrane vesicles from a low metastatic lymphoma (Eb) and its high metastatic variant (ESb): inhibitory capacity in cell-cell interaction systems. (1986) (14)
- Immunoresistant metastatic tumor variants can re‐express their tumor antigen after treatment with DNA methylation‐inhibiting agents (1986) (14)
- Multimodal Cancer Therapy Involving Oncolytic Newcastle Disease Virus, Autologous Immune Cells, and Bi-Specific Antibodies (2014) (13)
- Adhesive function of newcastle-disease virus hemagglutinin in tumor-host interaction. (1995) (13)
- In vitro Studies on Tumor Cell Interaction with the Vascular Endothelium and the Subendothelial Basal Lamina: Relationship to Tumor Cell Metastasis (1983) (13)
- Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies (1996) (13)
- Cytotoxic immune cells with specificity for defined soluble antigens. I. Assay with antigen-coated target cells. (1973) (13)
- Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience (2020) (13)
- Therapy of human tumors in NOD/SCID mice with patient derived re-activated memory T cells from bone marrow (2001) (13)
- Effects of mutagens on the immunogenicity of murine tumor cells: immunological and biochemical evidence for altered cell surface antigens. (1985) (13)
- T cell-mediated immunotherapy of metastases: state of the art in 2005 (2005) (13)
- Detection and Functional Analysis of Tumor Infiltrating T-Lymphocytes (TIL) in Liver Metastases from Colorectal Cancer (2008) (13)
- Harnessing Oncolytic Virus-Mediated Anti-Tumor Immunity (2014) (12)
- Cancer-reactive memory T cells from bone marrow: Spontaneous induction and therapeutic potential (Review). (2015) (12)
- Superiority of the ear pinna over a subcutaneous tumour inoculation site for induction of a Th1-type cytokine response (1998) (12)
- Breaking tolerance to a tumor‐associated viral superantigen as a basis for graft‐versus‐leukemia reactivity (2000) (12)
- Cytotoxic immune cells with specificity for defined soluble antigens. 3. Separation from helper cells and from antibody-forming cell precursors. (1973) (12)
- Murine Fcγ receptor proteins: identification of a previously unrecognized molecule with a monoclonal antibody (12‐15) (1988) (11)
- Characterization of a murine lymphoma cell line by 31P‐NMR spectroscopy: In vivo monitoring of the local anti‐tumor effects of systemic immune cell transfer (1996) (11)
- Determination of cell-free interleukin 2 receptor level in the serum of normal animals and of animals bearing IL-2 receptor positive tumours with high or low metastatic capacity. (1987) (11)
- TPA-Induced Modulation of B Cell Differentiation Antigens Defined by Monoclonal Antibodies (HD6, HD28, HD37, HD39) (1986) (11)
- Purification and identification of chemokines potentially involved in kidney-specific metastasis by a murine lymphoma variant: induction of migration and NFkappaB activation. (1998) (11)
- New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection (2020) (11)
- Antagonistic effects of systemic interleukin 2 on immune Tcell-mediated graft-versus-leukemia reactivity. (1998) (11)
- Quantitative determination of disseminated tumor cells by [3H]thymidine incorporation in vitro and by agar colony formation. (1982) (10)
- Fibrin autography of plasminogen activator by electrophoretic transfer into fibrin agar gels. (1988) (10)
- Immunobiology and Immunotherapy of Cancer Metastases Ten-Year Studies in an Animal Model Resulting the Design of an Immunotherapy Procedure now under Clinical Testing (1989) (10)
- A novel tumour model system for the study of long-term protective immunity and immune T cell memory. (2003) (10)
- Characteristics of a potent tumor vaccine-induced secondary anti-tumor T cell response. (2004) (10)
- A T-cell-related proteinase expressed by T-lymphoma cells activates their endogenous pro-urokinase. (1992) (10)
- [Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization]. (1995) (10)
- Quantitative analysis of cancer invasion in vitro: comparison of two new assays and of tumour sublines with different metastatic capacity (1986) (9)
- Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25. (2010) (9)
- Foreign H-2-like molecules on a murine tumor (MCG4): target antigens for alloreactive cytolytic T lymphocytes (CTL) and restricting elements for virus-specific CTL. (1980) (9)
- A model to account for the effects of oncogenes, TPA, and retinoic acid on the regulation of genes involved in metastasis (1988) (9)
- Expression and enhanced secretion of proteochondroitin sulphate in a metastatic variant of a mouse lymphoma cell line. (1988) (9)
- New plasma membrane proteins expressed by a high metastatic variant of a chemically induced tumor. (1984) (9)
- Enrichment of functional CD8 memory T cells specific for MUC1 in Bone Marrow of Multiple Myeloma Patients (2004) (9)
- Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals (2014) (9)
- Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus. (2004) (9)
- Matrix heparan sulphate, but not endothelial cell surface heparan sulphate, is degraded by highly metastatic mouse lymphoma cells. (1988) (9)
- Identification of four genes in endothelial cells whose expression is affected by tumor cells and host immune status : A study in ex vivo-isolated endothelial cells (1998) (9)
- A syngeneic anti tumor serum recognizing a complex H-2 alloantigen. (1979) (8)
- Identification of four genes in endothelial cells whose expression is affected by tumor cells and host immune status--a study in ex vivo-isolated endothelial cells. (1998) (8)
- Genetic separation of GvL and GvH reactivity in new recombinant-inbred tumor-resistant mouse strains. (1996) (8)
- The synthesis of radioactively labeled sulfanyl‐N‐chloracetyl tyrosine and its use for determinations of quantities and affinities of anti‐p‐azobenzenesulfonate antibodies (1972) (8)
- Postoperative active-specific immunotherapy of lymph node micrometastasis in a guinea pig tumor model. (1989) (8)
- The Immune Response against Hapten‐Autologous Protein Conjugates in the Mouse (1973) (8)
- Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. I. Effect of incompatibilities at H-2 or non-H-2 genes in normal and nude (nu/nu) mice. (1981) (8)
- Analysis of metastatic competence of mouse bladder carcinoma cells after transfection with activated Ha-ras or N-ras oncogenes (1988) (8)
- Changes in liver glycogen and lipid metabolism during transient graft-versus-host (GvH) and graft-versus-leukemia (GvL) reactivity. (1996) (7)
- Spontaneous Phenotypic Shifts from Low to High Metastatic Capacity (1983) (7)
- Affinity fractionation of lymphoid cells according to type and function. (1972) (7)
- Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus (2022) (7)
- A RADIOASSAY FOR MACROPHAGES AND ITS APPLICATION FOR TESTING MACROPHAGE MEMBRANE ANTIGENS (1975) (7)
- Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. 2. Characteristics of a metastasizing variant of a chemically induced lymphoma. (1979) (7)
- Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines (2005) (7)
- Danger signals in tumor cells: a risk factor for autoimmune disease? (2010) (7)
- Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients (2022) (7)
- In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: Intra-pinna immunization followed by restimulation in the peritoneal cavity (2005) (7)
- Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase. (1992) (7)
- EXPRESSION OF FOREIGN H‐2‐LIKE ANTIGENS BY A CHEMICALLY‐INDUCED MURINE TUMOUR (MCG4) (1980) (7)
- An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules (1999) (7)
- Tumours of the spine (2012) (7)
- Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: Migration, survival and tumor-protectivity of cytotoxic donor cells (1991) (7)
- Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counteracting Treg activity (2011) (6)
- Novel adenomatous polyposis coli gene promoter is located 40 kb upstream of the initiating methionine. (2005) (6)
- Clonal analysis of H-2 antigen expression by variants of a chemically induced murine tumor. (1981) (6)
- Alloantibody production by nude mice. (1980) (6)
- Mechanisms of metastatic spread to liver. (1986) (6)
- Newcastle Disease Virus: A Promising Vector for Viral Therapy of Cancer (2008) (6)
- Metastatic tumor cell variants with increased resistance to infection by Semliki Forest virus. (1981) (6)
- Active Specific Immunotherapy – A New Modality of Cancer Treatment Involving the Patient’s Own Immune System (1993) (6)
- Induction of anti-hapten antibody responses against haptens conjugated to autologous and heterologous proteins. (1973) (6)
- Intra-pinna induction of specific antitumor immune T cell functions. (1997) (6)
- Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine. (2010) (6)
- Superantigen reactive Vβ6+ T cells induce perforin/granzyme B mediated caspase-independent apoptosis in tumour cells (2002) (6)
- Biotherapy of cancer. Perspectives of immunotherapy and gene therapy. (1995) (6)
- Ear Pinna : a privileged DNA electroporation site for inducing strong Th1 immune responses (2009) (5)
- Peripheral immunization against malignant rat glioma can induce effective antitumor immunity in the brain. (1995) (5)
- Effect of thymic factor on human lymphoid cells of umbilical cord blood and of children with T cell deficiency. (1977) (5)
- Phenotypic and genotypic differences between high- and low-metastatic related tumor lines and the problem of tumor progression and variant generation. (1983) (5)
- This information is current as Memory T Cells Effector + and CD 4 + Peripheral Blood CD 8 Dynamic Differentiation of Activated Human and (2005) (5)
- In situ analysis of tumor-specific CTL effector and memory responses elicited by tumor vaccination. (1999) (5)
- Tumor-immune memory T cells from the bone marrow exert GvL without GvH reactivity in advanced metastasized cancer. (2005) (5)
- Prolongation of survival of mice bearing the Eb and ESb lymphoma by treatment with interferon inducers alone or in combination with Corynebacterium parvum (2004) (5)
- Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene (2004) (5)
- [Adjuvant therapy of liver metastases: active specific immunotherapy]. (1995) (5)
- Clonal analysis of expression of tumor-associated transplantation antigens and of metastatic capacity (2004) (5)
- Immunotherapy of metastases. (1996) (5)
- H-2 histocompatibility antigens of subcellular membranes of mouse liver. (1979) (4)
- Change in organotropism of mouse lymphoma variants associated with selective chemotactic responsiveness to organ-derived chemoattractants (1991) (4)
- A NEW S ENSITIVE ASSAY FOR ANTIBODY AGAINST CELL SURFACE ANTIGENS BASED ON INHIBITION OF CELL-DEPENDENT A NTIBODY-MEDIATE D CYTOTOXICITY I. Specificity and Sensitivity* (1974) (4)
- Fc receptors and Ia antigens. (1976) (4)
- Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy. (1998) (4)
- Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta. (1993) (4)
- Local Tumor Growth and Spontaneous Systemic T Cell Responses in Cancer Patients: A Paradox and Puzzle (2008) (4)
- Characterization of antigens on murine tumor cells reacting with alloantisera against foreign H-2 specificities: analysis by absorption with purified murine leukemia virus and normal lymphoid cells of different H-2 haplotypes. (1978) (4)
- Liver endothelial cells: participation in host response to lymphoma metastasis (1996) (4)
- Expression of RIGI , IRF 3 , IFN-ß and IRF 7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus (4)
- A fast-acting cytotoxin derived from Con A-activated porcine leukocytes. I. Biochemical characteristics and target cell specificity. (1986) (4)
- Species-restricted antibody response against a DNA-construct coding for aspartic proteinase from Schistosoma japonicum (2002) (4)
- Antibodies induced in mice by a DNA-construct coding for the elastase of Schistosoma mansoni recognize the enzyme in secretions and preacetabular glands of cercariae (2002) (4)
- Adoptive transfer of protective immunity against a high metastatic tumor-cell variant by small numbers of tumor-specific in-situ activated peritoneal effector T-cells. (1994) (4)
- Tumor Antigen-Dependent and Tumor Antigen-Independent Activation of Antitumor Activity in T Cells by a Bispecific Antibody-Modified Tumor Vaccine (2011) (4)
- Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit (2020) (4)
- Effects of RA 233 treatment on the adhesive, invasive and metastatic properties of 13762NF rat mammary tumor cells (1989) (3)
- 4-year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous administration of recombinant interleukin-2 and interferon-alpha2b (1995) (3)
- Antitumor Immune Memory And Its Activation For Control Of Residual Tumor Cells And Improvement Of Patient Survival: A New Concept Derived From Translational Research With The Virusmodified Tumor Vaccine Atv-Ndv (2004) (3)
- Regulation of plasminogen-activator in mastocytoma cells by lymphokines. (1983) (3)
- The relationship between alloantigen responses in nude mice injected with a low number of congenic thymus cells. (1980) (3)
- Biotechnological production and functional characterization of leukocytic cytokine(s) with cytotoxic effect on resting but not activated thymocytes. (1985) (3)
- In situ downregulation of VLA-4 integrin cell surface expression during lymphoma growth and liver metastasis. (1997) (3)
- Mechanism of Transendothelial Cell Passage and Matrix Degradation by Metastatic Tumor Cells (1987) (3)
- A radioassay for the study of cell surface determinants on activated lymphocytes. (1975) (3)
- Preferential antibody targeting to small lymphoma metastases in the absence of the primary tumour. (1993) (3)
- In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells (1993) (3)
- Interaction of high or low metastatic related tumor lines with normal or lymphokine-activated syngeneic peritoneal macrophages:in vitro analysis of tumor cell binding and cytostasis (2005) (3)
- TUMOR METASTASES AND CELL-MEDIATED IMMUNITY IN A MODEL SYSTEM IN DBA/2 MICE 3. INDUCTION AND SPECIFICITY OF SYNGENEIC CYTOTOXIC T CELLS (1979) (3)
- THE EXPRESSION OF H‐2K, H‐2D AND Ia ANTIGENS IN VARIOUS TISSUES AS ASSESSED IN Fc RECEPTOR INHIBITION SYSTEMS (1975) (3)
- Virus spike protein complexes and virosomes as effective subunit vaccines. (1979) (3)
- Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer (2012) (3)
- Augmentation of protective immunotherapy against metastatic esb lymphoma-cells by combining immune cell transfer with host irradiation, antigen restimulation and/or anti-tnf-alpha antibody treatment. (1995) (3)
- Unexpected H-2 antigen expression by mouse tumor cells, a cautionary note (2004) (2)
- Studies on the expression of cell surface determinants on activated mouse lymphocytes (1976) (2)
- IN VITRO INVASION OF LYMPHOMAS WITH DIFFERENT METASTATIC CAPACITY (1982) (2)
- 14C-thymidine release assay: a new test for the study of surface determinants on activated lymphocytes. (2008) (2)
- Adoptive transfer via immune T-lymphocytes of effective anti-tumor immunity against a malignant rat glioma in the brain. (1997) (2)
- Generation of adhesive tumor variants: Chromosomal changes, reduction in malignancy and increased expression of a distinct membrane glycoprotein (1988) (2)
- [Tumor cell immunogenicity and T-cell-mediated antitumor immune reactions. Modulation and application to immunotherapy]. (1987) (2)
- Immunological and molecular characterization of an aggressive murine lymphoma variant: modulation in vitro and in vivo. (1999) (2)
- EXPRESSION OF H-2 SPECIFICITIES AND OF MuLV ENVELOPE ANTIGENS ON MURINE TUMORS (1977) (2)
- Heterogeneity of glycoprotein synthesis in human tumor cell lines. (1986) (2)
- Cancer metastasis and the use of animal model systems. (1984) (2)
- Clonal Tumor Cell Variants Arising by Adaptation (1980) (2)
- Molecular identification of lectin binding sites differentiating related low and high metastatic murine lymphomas (2005) (2)
- Murine lymphoma cells possess blood group Tn-, T-, N-, M- and S-active substances (1983) (2)
- Dendritic Cells Pulsed with Viral Oncolysate (2013) (2)
- ATIM-30. HOW TO MONITOR IMMUNOGENIC CELL DEATH IN PATIENTS WITH GLIOBLASTOMA (2018) (2)
- Quo vadis cancer therapy (2017) (2)
- [Anti-tumor vaccination]. (2000) (2)
- Quantitation of antibody uptake in spontaneous metastases. (1990) (2)
- [Invasive, metastatic growth of lymphoblastoid B cells in immunodeficient SCID mice]. (1991) (2)
- Position paper: new insights into the immunobiology and dynamics of tumor–host interactions require adaptations of clinical studies (2020) (2)
- Oncogene expression in related cancer lines differing in metastatic capacity (1988) (2)
- Cancer metastasis : molecular and cellular biology, host, immune response, and perspectives for treatment (1989) (2)
- T cell based immunotherapy – Changes and challenges (2006) (1)
- Dissection of tumor and host cells from metastasized organs for testing gene expression directly ex vivo. (2001) (1)
- Transforming growth factor-beta production and induction of cellular responses in 13762NF rat mammary adenocarcinoma cell clones. (1993) (1)
- DIPG-10. MULTIMODAL IMMUNOTHERAPY AS PART OF MULTIMODAL TREATMENT FOR DIPG (2017) (1)
- Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells derived from bone marrow (2005) (1)
- Sequential treatment of patients with advanced renal cell carcinoma with autologous tumor vaccine and subcutaneous administration of recombinant interleukin-2 and interferon α2b (1991) (1)
- Virus modified tumor cell vaccines for active specific immunotherapy of micrometastases: expansion and activation of tumor-specific T cells. (1989) (1)
- Immune responses against native and chemically modified albumins in mice. II. Effect of electric charge and conformation on the humoral antibody response and on helper T cell responses. (1974) (1)
- Dissection of tumour and host cells from target organs of metastasis for testing gene expression directly ex vivo. (1996) (1)
- Assay for the determination of human carcinoma cells in circulating blood (2004) (1)
- Induction of the metastatic phenotype by transfection of the nuclear oncogene p53: Increases in cytoplasmic diacylglycerol levels and reduction in class I major histocompatibility antigen expression are not sufficient to explain the changes in metastatic capacities (2004) (1)
- The specificity and significance of the inhibition of Fc receptor binding by anti H-2 sera (1975) (1)
- Protective Immunity against Metastasis: Basic Studies and Clinical Application (1992) (1)
- Biotherapy of cancer (1995) (1)
- Scientific Proceedings Fifth Symposium of the Section of Experimental Cancer Research (SEK) of the German Cancer Society (2004) (1)
- Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells (MTC) derived from bone marrow (BM) (2004) (1)
- A fast-acting cytotoxin derived from Con A-activated porcine leukocytes. II. Mechanism of target cell lysis. (1986) (1)
- Workshop: Active Specific Immunotherapy with Tumor Cell Vaccines (2005) (1)
- Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice (2005) (1)
- Changes in metastasis formation and distinct cell surface molecules in adhesion variants of a metastatic murine tumor. (1988) (1)
- Generation of Stable Antigen Loss Variants from Cloned Tumor Lines—An Example of Immunoadaptation During Metastasis (1981) (1)
- Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy (2022) (1)
- Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells (MTC) derived from bone marrow (BM). (2004) (1)
- Successful Application of a Virus-Modified Tumor Vaccine for Anti-Metastatic Cancer Immunotherapy (1989) (1)
- Second international conference on cancer vaccines/adjuvants/delivery for the next decade (CVADD): Heidelberg, Germany, 10–12 October 2007 (2008) (1)
- IMMU-07. IMMUNOGENIC CELL DEATH DURING MAINTENANCE CHEMOTHERAPY AND SUBSEQUENT MULTIMODAL IMMUNOTHERAPY FOR GBM (2018) (1)
- CELL SURFACE DETERMINANTS—NEW METHODS OF DETECTION AND BIOLOGICAL IMPLICATIONS: A GENERAL SURVEY (1975) (1)
- Time for cancer Immunotherapy (2018) (1)
- In Vitro Interactions of Aortic Endothelial Cell Monolayers with Tumor Cell Lines of Different Invasive and Metastatic Capacity (1983) (1)
- A Role for Cell Surface Sialic Acid in Liberating Metastatic Tumor Cells from Host Control (1986) (1)
- Foreign H-2-like ,olecules on a murine tumor (MCG4) (1980) (0)
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience (2023) (0)
- [Immunotherapy of hemato-oncologic diseases]. (1996) (0)
- Human T Cell Leukemia Virus-I ( HTLV-I ) Tax-Mediated Apoptosis in Activated T Cells Requires an Enhanced Intracellular Prooxidant State 1 (1998) (0)
- Bispecific antibody modified tumor veaccine for human T cell stimulation (1997) (0)
- Requires an Enhanced Intracellular Tax-Mediated Apoptosis in Activated T Cells Human T Cell Leukemia Virus-I (HTLV-I) (2013) (0)
- HGG-05. CAN MULTIMODAL IMMUNOTHERAPY REPLACE RADIOCHEMOTHERAPY IN COMPLETELY RESECTED ADULT GBM? (2017) (0)
- Multimodal immunotherapy for DIPG: status today (2016) (0)
- Activation of Tumor‐Specific CTLP to a Cytolytic Stage Requires Additional Signals (1988) (0)
- Different H-2 antigens expressed on two tumors derived from one BALB/c mouse. (1981) (0)
- Subject Index Vol. 108, 1995 (1995) (0)
- Cell Biology of Tumor Metastasis Formation (1989) (0)
- Effective introduction of T cell costimulatory molecules into virus modified tumor cell vaccines by modification with bispecific antibodies. (1997) (0)
- Models for Immunotherapy and Cancer Vaccines (2005) (0)
- Functional tumor reactive T cells in bone marrow and blood of pancreatic cancer patients (2005) (0)
- Tumor epitope detection in monocytes (EDIM) as a marker for antitumoral activity of Newcastle disease virus infusion and modulated electrohyperthermia (2018) (0)
- Effects of adjuvant therapies in breast cancer on tumor specific memory T cells (MTC) derived from bone marrow (bm) (2003) (0)
- DIPG-38. ADDITION OF MULTIMODAL IMMUNOTHERAPY TO COMBINATION TREATMENT STRATEGIES FOR CHILDREN WITH DIPG: FINAL RESULTS OF A COHORT OF CHILDREN (2020) (0)
- Virus Superantigen Increases Tumor Resistance Loss of Endogenous Mouse Mammary Tumor (1998) (0)
- Treatment of Patients with Advanced Renal Cell Carcinoma with Autologous Tumor Vaccine and Subcutaneous Administration of Recombinant Interleukin-2 and Interferon-alpha2b, Survival Data (1995) (0)
- Postoperative activation of tumor specific T cells by immunization with virus-modified tumor cells and effects on metastasis. (1988) (0)
- Studies on the specificity of cooperating thymus derived cells (1972) (0)
- O-81 Interactions of tumorantigen-reactive T-cells derived from bone marrow and tumor-cells in breast cancer patient (2007) (0)
- Current Cancer Research 1986 (1986) (0)
- 7th International Symposium of the Division of Experimental Cancer Research (AEK) of the German Cancer Society (1994) (0)
- Modulations of tumor cell immunogenicity resulting in increase of t cell reactivity (1985) (0)
- Cell surface glycoprotein differences between a highly malignant murine tumor line and a plastic-adherent, less malignant variant. (1987) (0)
- P102 Cellular immunotherapy in late stage breast cancerpatients with reactivated autologous Memory T-cells derived from bone marrow (2005) (0)
- II. International Congress of the Metastasis Research Society, Heidelberg, 26–29 September 1988 (1989) (0)
- Cytotoxin with anti tumor activity produced by porcine peripheral blood leukocytes studies on its specificity mode of action and physical properties (1985) (0)
- Clinical perspectives for the treatment of metastases (1989) (0)
- Experimental Basis for Immunotherapy of Metastases (1998) (0)
- [Effect of imidazole derivatives and other 5-membered heterocyclic compounds on adenine phosphoribosyltransferase]. (1967) (0)
- Immunological effects after an adoptive cellular immunotherapy with reactivated autologous memory T-Cells from bone marrow. (2006) (0)
- Change in metastasis and organotropism of mouse lymphoma variants associated with changes in expression of adhesion molecules and chemotactic responsiveness (1991) (0)
- IMMU-25. SYNERGY BETWEEN TMZ AND INDIVIDUALIZED MULTIMODAL IMMUNOTHERAPY TO IMPROVE OS OF IDH1 WILD TYPE MGMT PROMOTOR UNMETHYLATED GBM PATIENTS (2021) (0)
- Immunological aspects in oncology (1989) (0)
- Dissection oftumourandhostcells fromtarget organsofmetastasis for testing geneexpression directly ex vivo (1996) (0)
- Superantigen recognition facilitating graft versus leukemia reactivity leading to complete remissions (1998) (0)
- Evolution of the Leukemic State Group Report (1985) (0)
- P15 Interactions of tumorantigen-reactive T-cells derived from bone marrow and tumor-cells in breast cancer patients (2007) (0)
- Interactions of breast cancer cells and tumorantigen-reactive T-cells derived from bone marrow (2007) (0)
- Late abstracts 186–187 (2005) (0)
- Cytologic and flow cytometric DNA analysis of multinucleated tumor cells and derived microcells. (1989) (0)
- [Cell biology principles of metastasis and strategies for immunotherapy]. (1989) (0)
- Improvement of Anti-Tumor DNA Vaccination by Co-Immunization at a Distant Site with a Plasmid Encoding the Hemagglutinin-Neuraminidase Protein of Newcastle Disease Virus (2010) (0)
- Sulfated glycosaminoglycans accelerate the activation of PRO-uPA and plasminogen and stimulate in vitro invasion of tumor cells (1989) (0)
- Modulated electrohyperthermia as part of immunogenic cell death treatment in pediatric neuro-oncology (2019) (0)
- Differences in glycosidase spectrum between related tumor cell lines (1985) (0)
- VirusMonocytes Stimulated by Newcastle Disease Mediates Tumoricidal Activity of Human TNF-Related Apoptosis-Inducing Ligand (2003) (0)
- The Immun System, F. Melchers, K. Rajewsky (Eds.). Springer-Verlag, Berlin • Heidelberg • New York (1976), 104 figs., XII, 299 pages (27. Kolloquium, Ges. für Biol. Chemie 29. 4.-1. 5. 1976 in Mosbach). US-$ 21.70 (1979) (0)
- Interaction of Metastatic and Non-Metastatic Tumor Lines with Aortic Endothelial Cell Monolayer and Their Underlying Basal Lamina (1983) (0)
- Combined Vaccination with Autologous Tumor Material and Subcutaneously Administered rIL-2 and rIFN-α-2b in the Treatment of Renal Cell Carcinoma (1992) (0)
- Individualized Multimodal Immunotherapy for DIPG: Part of the Game (2021) (0)
- New Experimental Approaches to the Therapy of Metastasis in Tumor Model Systems (1988) (0)
- HG-21NEXT GENERATION IMMUNOTHERAPY FOR DIFFUSE INTRINSIC PONTINE GLIOMA. (2016) (0)
- Contents, Vol. 108, 1995 (1995) (0)
- Cell adhesion and migration of different human colon cell lines and primary tumors (2004) (0)
- immune status studied with a lacZ transduced lymphoma Pattern and load of spontaneous liver metastasis dependent on host (2011) (0)
- Multimodal immunotherapy integrated into standard therapy for GBM: learning from clinical practice (2018) (0)
- [Tumor vaccines and active specific immunotherapy]. (1997) (0)
- Isolated Endothelial Cells - A Study in Ex Vivo -- Affected by Tumor Cells and Host Immune Status Identification of Four Genes in Endothelial Cells Whose Expression Is (2013) (0)
- Prevention of postoperative metastic spread (1985) (0)
- Antibody-dependent cell-mediated cytotoxicity in the mouse. I. Surface characteristics of an effecter cell. (1974) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Volker Schirrmacher?
Volker Schirrmacher is affiliated with the following schools: